Engineered Aβ Binding Polypeptides for Alzheimer's Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease provide only modest symptomatic relief and lack effective therapies that can slow or halt the progression of the disease, with conventional antibodies posing risks due to size and immune responses, necessitating safer and more efficient Aβ peptide binding agents.
Innovation Solution
Development of engineered Aβ peptide binding polypeptides with high affinity, comprising specific binding motifs and linkers, allowing for therapeutic, diagnostic, and prognostic applications while avoiding the drawbacks of conventional antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used for Aβ peptide binding, then high binding affinity can be achieved, but the large molecular size negatively affects in vivo biodistribution and brain uptake
Solution Approach 1:
The patent segments the antibody structure into smaller functional units by using only the antigen-binding fragments (scFv, Fab, or nanobody) without the full antibody molecule. This segmentation reduces molecular size from ~150 kDa to ~15-50 kDa while preserving the essential Aβ binding function, enabling better brain penetration and biodistribution.
Solution Approach 2:
The invention extracts and utilizes only the essential antigen-binding domain from the complete antibody structure. By removing the Fc region and other non-essential components, the patent creates minimized polypeptides that retain high affinity for Aβ peptides but have reduced molecular weight and improved tissue penetration capabilities.
2Reliability
If conventional antibodies are used for Aβ peptide binding, then therapeutic potential can be achieved, but severe side effects occur due to Fc-mediated pro-inflammatory immune responses
Solution Approach 1:
The invention removes the Fc region from the antibody structure, which is responsible for activating complement and engaging Fc receptors that mediate pro-inflammatory responses. By using only the antigen-binding fragments, the patent eliminates these harmful immune activation pathways while preserving the therapeutic ability to bind and neutralize Aβ peptides.
Solution Approach 2:
The patent converts the potential harm of full antibody use (immune activation) into benefit by selectively removing the harmful Fc-mediated pathways while retaining the beneficial antigen-binding function. This creates a therapeutically active molecule with improved safety profile by eliminating the source of side effects.
3Speed
If smaller scaffold proteins are used instead of antibodies, then faster transfer across the blood-brain barrier is achieved, but the binding affinity and efficacy may be reduced
Solution Approach 1:
The invention optimizes the parameters of the scaffold proteins by selecting or engineering domains with molecular weights specifically tuned for optimal brain penetration (15-50 kDa range).同时，通过定向进化或理性设计优化这些较小蛋白的Aβ结合位点，使其在保持小分子量的同时实现高亲和力结合。
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered polypeptides effectively inhibit Aβ peptide aggregation and plaques, offering potential therapeutic benefits and improved safety profiles, with high binding affinity and potential for faster brain penetration.
Implementation Method 1
engineered Aβ peptide binding polypeptides with high affinity, comprising specific binding motifs
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The present disclosure relates to a class of engineered polypeptides having a binding affinity for amyloid β (Aβ) peptides (in the following referred to as Aβ), comprising the amino acid sequence EX2X3YX5X6NLX9AX11QLCAX16IX18X19X20 ED. The present disclosure also relates to the use of such Aβ peptide binding polypeptides as therapeutic, prognostic and/or diagnostic agents.